Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22:10–8.

Article  CAS  PubMed  Google Scholar 

Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis—immune cell–fibroblast–bone interactions. Nat Rev Rheumatol. 2022;18:415–29.

Article  CAS  PubMed  Google Scholar 

Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292–304.

Article  CAS  PubMed  Google Scholar 

Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. JCR J Clin Rheumatol. 2005;11:S39–44.

Article  PubMed  Google Scholar 

Wong VKW. Editorial overview: new technologies in 2020: drug resistance. Curr Opin Pharm. 2020;54:iii–vi.

Article  CAS  Google Scholar 

Haroon N, Aggarwal A, Lawrence A, Agarwal V, Misra R. Impact of rheumatoid arthritis on quality of life. Mod Rheumatol. 2007;17:290–5.

Article  PubMed  Google Scholar 

Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–31.

Article  CAS  PubMed  Google Scholar 

Cooks T, Harris CC, Oren M. Caught in the cross fire: p53 in inflammation. Carcinogenesis. 2014;35:1680–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo G, Cui Y. New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy. J Immunother Cancer. 2015;3:9.

Article  PubMed  PubMed Central  Google Scholar 

Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol. 2016;16:741–50.

Article  PubMed  PubMed Central  Google Scholar 

Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89–102.

Article  CAS  PubMed  Google Scholar 

Thomasova D, Mulay SR, Bruns H, Anders H-J. p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia. 2012;14:1097–101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Binayke A, Mishra S, Suman P, Das S, Chander H. Awakening the “guardian of genome”: reactivation of mutant p53. Cancer Chemother Pharmacol. 2019;83:1–15.

Article  CAS  PubMed  Google Scholar 

Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci. 1997;94:10895–900.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847–60.

Article  CAS  PubMed  Google Scholar 

Butler JS, Loh SN. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry. 2003;42:2396–403.

Article  CAS  PubMed  Google Scholar 

Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2: a001107.

Article  PubMed  PubMed Central  Google Scholar 

Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39:494-508.e5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stiewe T, Haran TE. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resist Updates. 2018;38:27–43.

Article  Google Scholar 

Zhang KX, Ip CK, Chung SK, Lei KK, Zhang YQ, Liu L, et al. Drug-resistance in rheumatoid arthritis: the role of p53 gene mutations, ABC family transporters and personal factors. Curr Opin Pharm. 2020;54:59–71.

Article  CAS  Google Scholar 

He C, Li L, Guan X, Xiong L, Miao X. Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy. Chemotherapy. 2017;62:43–53.

Article  CAS  PubMed  Google Scholar 

Shetzer Y, Solomon H, Koifman G, Molchadsky A, Horesh S, Rotter V. The paradigm of mutant p53-expressing cancer stem cells and drug resistance. Carcinogenesis. 2014;35:1196–208.

Article  CAS  PubMed  Google Scholar 

Han Z, Boyle DL, Shi Y, Green DR, Firestein GS. Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum. 1999;42:1088–92.

Article  CAS  PubMed  Google Scholar 

Cheng X, Zhou T, Yang Z, Zhou J, Gao M, Huang Y, et al. Premature termination codon: a tunable protein translation approach. Biotechniques. 2022;73:80–9.

Article  CAS  PubMed  Google Scholar 

Shirole NH, Pal D, Kastenhuber ER, Senturk S, Boroda J, Pisterzi P, et al. Correction: TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions. Elife. 2017;6: e25532.

Article  PubMed  PubMed Central  Google Scholar 

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:1–21.

Article  Google Scholar 

Team RC. R: A language and environment for statistical computing. 2013.

Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS: J Integr Bio. 2012;16:284–7.

Article  CAS  Google Scholar 

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44:D457–62.

Article  CAS  PubMed  Google Scholar 

Mao X, Cai T, Olyarchuk JG, Wei LJB. Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. Bioinformatics. 2005;21:3787–93.

Article  CAS  PubMed  Google Scholar 

Kanehisa M, Sato Y, Kawashima MJPS. KEGG mapping tools for uncovering hidden features in biological data. Protein Sci. 2022;31:47–53.

Article  CAS  PubMed  Google Scholar 

Wickham H, Chang W, Wickham MHJCedvutgogV. Package ‘ggplot2’. 2016; 2:1–189.

Igarashi H, Hashimoto J, Tomita T, Yoshikawa H, Ishihara K. TP53 mutations coincide with the ectopic expression of activation-induced cytidine deaminase in the fibroblast-like synoviocytes derived from a fraction of patients with rheumatoid arthritis. Clin Exp Immunol. 2010;161:71–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–25.

Article  CAS  PubMed  Google Scholar 

Qiu C, Chan JTW, Zhang DW, Wong IN, Zeng Y, Law BYK, et al. The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations. Genes Dis. 2023;10:2252–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Bao W, Jiang F, Che Q, Chen Z, Wang F, et al. Mutant p53 (p53–R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGγ. Cancer Lett. 2015;360:269–79.

Article  CAS  PubMed  Google Scholar 

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2021;50:D439–44.

Article  PubMed Central  Google Scholar 

Naso MF, Tomkowicz B, Perry WL, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317–34.

Article  CAS  PubMed  PubMed Central  Google Scholar